drugset / Trial / NCT07617337
AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a first-in-human, Phase I, open-label, multicenter, multinational study, designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of AQUA07 when administered as single agent and in combination with lorlatinib in patients with ALK positive non-small cell lung cancer.
Timeline
- Start
- 2026-07-24
- Primary completion
- 2030-08-31
- Completion
- 2030-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AQUA07 | Unknown | — | Oral |
| Background | Lorlatinib | Small molecule | — | Oral |